Biotech RadarJobs updated

COMPANY

Umoja Biopharma

HQ: Seattle, WA source · umoja-biopharma.com ↗ · West Coast

Clinical Phase 2

Keywords: oncology B Cell Lymphoma Lymphoma Non-Hodgkin High Grade B Cell Lymphoma Richter Transformation Lymphoma Grade 3b Follicular Lymphoma Primary Mediastinal B Cell Lymphoma Diffuse Large B Cell Lymphoma Lymphoma, Non-Hodgkin (NHL) Lymphoma, Large B-Cell, Diffuse (DLBCL) Chronic Lymphocytic Leukemia Multiple Myeloma in Relapse Multiple Myeloma UB-VV400 UB-VV111 UB-VV500

Location: Seattle, WA · source · Oct 15, 2026

Profile checked Oct 10, 2026

$100.0MRaised (2 yrs)3Trials (company is sponsor)

Timeline

  1. Trial start 1: A Phase 1 Study of UB-VV500 With Rapamycin in Relapsed/Refractory Multiple Myeloma source ↗
  2. Trial start 1: A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies source ↗
  3. Trial start 1: A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies source ↗
  4. Raise Private equity round — Series C: $100M (total, as published), announced Jan 14, 2025. Source: company's own press page. source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $100.0M. Last 2 years.

Clinical trials (lead sponsor) 3

RecordTitlePhaseStatusStartPrimary completion
NCT07735533A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies1Recruiting2026-092031-08 (estimated)
NCT06528301A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies1RecruitingMar 10, 20252029-03 (estimated)
NCT07735546A Phase 1 Study of UB-VV500 With Rapamycin in Relapsed/Refractory Multiple Myeloma1Not yet recruitingOct 1, 2026Dec 31, 2029 (estimated)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback